Skip to content
Open in App
Actinogen Medical logo

Actinogen Medical

web2

Actinogen Medical is an Australian clinical-stage biotechnology company developing Xanamem, an...

Symbol · ACW
Company profile

About

Actinogen Medical is an Australian clinical-stage biotechnology company developing Xanamem, an experimental oral medicine intended to address cognitive impairment associated with Alzheimer's disease and depression. The compound inhibits an enzyme involved in regulating cortisol levels inside brain cells, a mechanism being investigated for potential effects on memory and cognition. Its clinical program includes the XanaMIA study in people with Alzheimer's disease and completed trials involving adults with major depressive disorder and impaired cognition. Actinogen studies whether its treatment can improve clinical outcomes rather than marketing an established medicine. Xanamem remains investigational and has not received regulatory approval for commercial use in any country.

Explore by sector

Explore this sector

Market identity

Exchange listings

Listing identities only. Orbitrum does not publish live prices or market performance on this public profile.

ExchangeSydneyPrimary symbol: ACW
Expert coverage

1 expert evaluated Actinogen Medical.

Orbitrum research

Experts evaluating Actinogen Medical

Explore the public profiles of experts who have evaluated this project.

Orbitrum Academy

Learn how to read a project assessment